- Details
Although intravitreal injections are considered a great advancement in the management of retinal diseases because they have potential to improve vision, endophthalmitis is a concern to a treating ophthalmologist.1,2 Previous studies have found a prevalence of postinjection endophthalmitis of 0% to 0.87%. The purpose of this study is to report the incidence, microbiological profile, antimicrobial susceptibility, clinical findings, management, and visual outcomes in patients with acute postinjection endophthalmitis (within 6 weeks) after anti-vascular endothelial growth factor and intravitreal injection of triamcinolone acetonide (IVTA).
Read more: Five-Year Incidence and Visual Outcomes in Postintravitreal Injection Endophthalmitis
- Details
To characterize the rate and pattern of age-related and glaucomatous neuroretinal rim area changes in subjects of African and European descent.
Read more: Rate and Pattern of Rim Area Loss in Healthy and Progressing Glaucoma Eyes
- Details
To determine whether vitrectomy surgery rates have changed over the past decade and factors affecting the odds of undergoing this procedure.
Read more: Rates of Vitrectomy among Enrollees in a United States Managed Care Network, 2001–2012
- Details
Subthreshold depression is highly prevalent in visually impaired older adults and an important risk factor for major depressive disorder.1 For early diagnosis and treatment, it is important to identify patients who are at high risk of having subthreshold depression. Former research found inconsistent results and prediction models were never validated externally.2 Therefore, the aim of this study was to assess comprehensively potential predictor variables by internally validating a prediction model for subthreshold depression in a European sample and validating this model externally in a comparable Australian sample.
Read more: Validated Prediction Model of Depression in Visually Impaired Older Adults
- Details
To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (nAMD).
- Details
Conjunctival myxoma is a rare benign tumor that accounts for <0.001% of conjunctival lesions.1 It is important to recognize this entity, because it might be associated with cardiac myxoma, which can be life threatening.2 Based on a series of 4 cases, Herwig et al2 recently described the new entity, the conjunctival stromal tumor (COST), with its name deduced from the well-known gastrointestinal stromal tumor, showing a partially similar immunomarker profile. Positive markers for COST include CD34, vimentin, and partially for CD68; negative markers include S100 and smooth muscle actin.
Read more: Conjunctival Stromal Tumor: Expansion of Findings in a Newly Described Entity